From Earlier: Roche Disappointed by the Actions of Illumina's Board of Directors

Roche

released the following statement in response to the announcement by Illumina, Inc.

that its Board of Directors has recommended that shareholders not tender their shares to Roche. On January 27, 2012, Roche commenced a tender offer to purchase all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.